Increased CD16 expression on NK cells is indicative of antibody-dependent cell-mediated cytotoxicity in chronic-active antibody-mediated rejection

被引:24
|
作者
Sablik, Kasia A. [1 ]
Litjens, Nicolle H. R. [1 ]
Klepper, Mariska [1 ]
Betjes, Michiel G. H. [1 ]
机构
[1] Erasmus MC, Dept Nephrol & Transplantat, Room NA2105,POB 2040, NL-3000 CA Rotterdam, Netherlands
关键词
Kidney transplantation; Biomarkers; Chronic active antibody mediated rejection; Circulating immune cells; TRANSPLANT GLOMERULOPATHY; T-CELLS; B-CELL; KIDNEY; BIOPSIES; SUBSETS; CLASSIFICATION; INFLAMMATION; TRANSCRIPTS; ACTIVATION;
D O I
10.1016/j.trim.2019.02.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic-active antibody mediated rejection (c-aABMR) contributes significantly to late renal allograft failure. The antibodies directed against donor-derived antigens, e.g. anti-HLA antibodies, cause inflammation at the level of the microvascular endothelium. This is characterized by signs of local activation of the complement system and accumulation of immune cells within the capillaries. Non-invasive biomarkers of c-aABMR are currently not available but could be valuable for early detection. We therefore analyzed the activation profiles of circulating T and B cells, NK cells and monocytes in the peripheral blood of 25 kidney transplant recipients with c-aABMR and compared them to 25 matched recipients to evaluate whether they could serve as a potential biomarker. No significant differences were found in the total percentage and distribution of NK cells, B cells and T cells between the c-aABMRpos and c-aABMRneg cases. There was however a higher percentage of monocytes present in c-aABMRpos cases (p < .05). Additionally, differences were found in activation status of circulating monocytes, NK cells and gamma delta T cells, mainly concerning the activation marker CD16. Although statistically significant, these differences were not sufficient for use as a biomarker of c-aABMR.
引用
收藏
页码:52 / 58
页数:7
相关论文
共 50 条
  • [21] ROLE OF ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY IN RENAL-ALLOGRAFT REJECTION
    DAPICE, AJF
    MORRIS, PJ
    TRANSPLANTATION, 1974, 18 (01) : 20 - 26
  • [22] Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity
    Binder, Christian
    Sellberg, Felix
    Cvetkovski, Filip
    Berg, Stefan
    Berglund, Erik
    Berglund, David
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [23] Antibody-dependent cell-mediated cytotoxicity: A FCM-based assay for human NK cells
    Hesselbach, P
    Jahny, M
    Sack, U
    Woetzel, M
    CYTOMETRY PART A, 2004, 60A (02): : 205 - 205
  • [24] REVERSIBLE BLOCKING OF ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
    SUGAMURA, K
    SMITH, JB
    CELLULAR IMMUNOLOGY, 1977, 30 (02) : 353 - 357
  • [25] MULTIPLE NON-HLA ANTIBODIES ARE SIGNIFICANTLY INCREASED IN CHRONIC-ACTIVE ANTIBODY-MEDIATED REJECTION
    Sablik, Kasia
    Kamburova, Elena
    Roelen, Dave
    Otten, Henny
    Betjes, Michiel
    TRANSPLANT INTERNATIONAL, 2019, 32 : 155 - 155
  • [26] ENZYMATIC ENHANCEMENT OF CELL-MEDIATED CYTOTOXICITY AND ANTIBODY-DEPENDENT CELL CYTOTOXICITY
    KEDAR, E
    ORTIZDEL.M
    FAHEY, JL
    JOURNAL OF IMMUNOLOGY, 1974, 112 (01): : 26 - 36
  • [27] ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY IN INSULIN DEPENDENT DIABETES
    LUDWIG, H
    KRAFT, D
    SCHERNTHANER, G
    SCHEINER, O
    MAYR, WR
    DIABETOLOGIA, 1977, 13 (04) : 415 - 415
  • [28] NEUTROPHIL MEDIATED CYTOTOXICITY - MECHANISMS OF ANTIBODY-DEPENDENT CELL-MEDIATED CYTOLYSIS
    GREENE, WH
    ANTON, A
    ROOT, RK
    CLINICAL RESEARCH, 1979, 27 (02): : A345 - A345
  • [29] EFFECTOR CELL IN HUMAN ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
    YUST, I
    MANN, DL
    WUNDERLI.J
    FEDERATION PROCEEDINGS, 1974, 33 (03) : 780 - 780
  • [30] Natural Killer (NK) Cell Expression of CD2 as a Predictor of Serial Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
    Tang, Jennifer J. -J.
    Sung, Alexander P.
    Guglielmo, Michael J.
    Navarrete-Galvan, Lydia
    Redelman, Doug
    Smith-Gagen, Julie
    Hudig, Dorothy
    ANTIBODIES, 2020, 9 (04) : 1 - 18